Redox dual-responsive paclitaxel-doxorubicin heterodimeric prodrug self-delivery nanoaggregates for more effective breast cancer synergistic combination chemotherapy

This publication has 39 references indexed in Scilit:

• Co-delivery of doxorubicin and paclitaxel by PEG-polypeptide nanovehicle for the treatment of non-small cell lung cancer
  Biomaterials, 2014
• pH- and thermosensitive thin lipid layer coated mesoporous magnetic nanoassemblies as a dual drug delivery system towards thermochemotherapy of cancer
  Acta Biomaterialia, 2014
• Codelivery of Doxorubicin and Paclitaxel by Cross-Linked Multilamellar Liposome Enables Synergistic Antitumor Activity
  Molecular Pharmaceutics, 2014
• Nanoparticles for Combination Drug Therapy
  ACS Nano, 2013
• Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles
  Biomaterials, 2011
• Development of Novel Combination Therapies
  New England Journal of Medicine, 2011
• Mechanisms of drug combinations: interaction and network perspectives
  Nature Reviews Drug Discovery, 2009
• Protective effect of lycopene on adriamycin-induced cardiotoxicity and nephrotoxicity
  Toxicology, 2006
• Anticancer therapeutics: “Addictive” targets, multi-targeted drugs, new drug combinations
  Drug Resistance Updates, 2005
• Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
  Pharmacological Reviews, 2004